Excess Oral Doses Of Acurox(R) Tablets Are Disliked By Subjects With A History Of Opioid Abuse

King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) presented the results from an oral abuse liability study of Acurox® (oxycodone HCl/niacin) Tablets, AP-ADF-111 (Study 111), at the American Society of Addiction Medicine’s (ASAM) Medical-Scientific Conference. The results of Study 111 demonstrate that Acurox® Tablets are disliked among people with a history of opioid abuse compared to oxycodone HC1 tablets alone, when excess doses are swallowed. Dr.

More: continued here

Filed under: Alcohol / Addiction / Illegal Drugs on May 5th, 2009